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Abstract
Purpose Recent trial results are in favor of aggressive lipid
lowering using high dose statins in patients needing
secondary prevention. It is unclear whether these effects
are solely due to more extensive lipid lowering or the result
of the potentially anti-inflammatory properties of statins.
We aimed to determine whether aggressive compared with
conventional statin therapy is more effective in reducing
systemic markers of inflammation and oxidative stress.
Materials and methods This was a multi-centre, double-
blind, placebo-controlled trial. Patients with previous car-
diovascular disease, who did not achieve low density
lipoprotein (LDL) cholesterol levels <2.6 mmol/l on con-
ventional statin therapy (simvastatin 40 mg) were random-
ized to continue with simvastatin 40 mg or to receive
atorvastatin 40 mg for 8 weeks and thereafter atorvastatin
80 mg for the final 8 weeks (aggressive treatment). Lipids,
C-reactive protein, soluble cellular adhesion molecules,
neopterin, von Willebrand Factor, and antibodies against
oxidized LDL were measured at baseline and after 16 weeks.
Results Lipid levels decreased significantly in the aggres-
sive treatment group (LDL-C reduction 20.8%; P<0.001),
whereas a slight increase was observed in the conventional
group (LDL-C increase 3.7%; P=0.037). A significant
reduction in antibodies against oxidized LDL was seen in
the aggressive (13.4%; P<0.001) and the conventional
(26.8%; P<0.001) group, but there was no difference
between groups (P=0.25). Furthermore, no significant
differences in change in other biomarkers was observed
between both groups.
Conclusions This study does not support the hypothesis
that a more profound reduction in inflammatory and








Recent trials have emphasized the need for intensive lipid
lowering with hydroxymethylglutaryl-CoA reductase inhib-
itors (statins) in subjects with cardiovascular disease (CVD)
[1, 2]. One of the potential mechanisms contributing to the
beneficial effects of lipid lowering in these patients is a
reduction of inflammatory and/ or oxidative stress. This
effect may be due to extensive immunomodulatory proper-
ties that operate independently of lipid lowering (pleiotro-
pic effect) [3] or solely be the result of the reduction in lipid
levels [4].
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PO Box 616, 6200 MD Maastricht, The NetherlandsIt has been well established that atherosclerosis is a
chronicinflammatorydisorder[5], with oxidized low-density
lipoprotein (LDL) cholesterol being one of the most potent
inducers of inflammation [6]. Several biomarkers of inflam-
matory or oxidative stress have been recognized as powerful
predictors of outcome in cardiovascular disease making
them useful for reflecting the disease severity in clinical
studies [7]. Among these biomarkers are antibodies against
oxidized LDL (anti-oxLDL), C-reactive protein (CRP),
neopterin (a marker of monocyte activation), von Willebrand
Factor (vWF), and the soluble forms of cellular adhesion
molecules such as endothelial-selectin (s-E-selectin) and
intercellular adhesion molecule-1 (s-ICAM-1).
There is substantial clinical evidence that statins exhibit
anti-inflammatory effects. Although this effect is thought to
be unrelated to their lipid lowering properties, this is still a
matter of debate [8, 9]. A currently unsolved issue in
secondary prevention of vascular disease is whether the
beneficial effects of additional, aggressive lipid lowering as
observed in recent trials are the result of a reduction in
inflammatory and oxidative stress or that of a greater lipid
lowering effect per se. This study was undertaken to
evaluate the effects of aggressive versus conventional




The Simvastatin To Atorvastatin switch Trial (STAT) was a
double-blind, parallel-group, randomized, multi-centre trial
in 235 male and female patients with any clinical mani-
festation of atherosclerosis, and LDL-cholesterol (LDL-C)
levels >2.6 mmol/l despite simvastatin 40 mg mono
therapy. In addition to the principal center, the University
Medical Center Groningen, ten general hospitals in The
Netherlands participated in this study. The study was per-
formed between September 1998 and July 2001, and it has
therefore not been registered at a Trial Registration website.
Eligible patients were identified through screening the
out-patient population of the participating centers. If
eligible, patients entered a 4-week run-in period in which
they received simvastatin 40 mg once daily. Baseline
measurements regarding lipids, anti-oxLDL and inflamma-
tion were performed following these 4 weeks. Subsequent-
ly, patients entered a 16-week treatment phase starting on
atorvastatin 40 mg or continuing with simvastatin 40 mg.
After 8 weeks of treatment the dosage of atorvastatin was
increased to 80 mg, whereas the dosage of simvastatin
remained stable at 40 mg. Patients were kept on this dose
for the remaining 8 weeks of the treatment period.
Eligibility
Eligible patients were 30–75 years of age and had been
using a combination of a lipid-lowering diet and simvastatin
40 mg monotherapy once daily at bedtime for at least
8 weeks prior to the screening visit, after which LDL-C
levels remained above 2.6 mmol/l. In addition, all patients
had been diagnosed with a clinical manifestation of
atherosclerosis, which was defined as the patient having a
history of at least one of the following items: angina pectoris
with an abnormal bicycle test and/or nuclear stress test,
suspect for inducible myocardial ischaemia, or with a
significant stenosis in the coronary arterial system on coro-
nary angiography; myocardial infarction; percutaneous
transluminal coronary angioplasty (PTCA); coronary artery
bypass graft; transient ischaemic attack; carotid endarteriec-
tomy; abdominal aortic aneurysm; symptomatic peripheral
arterial obstructive disease, as evidenced by a lowered ankle-
brachial index (ABI<0.9), or by previous percutaneous or
surgical interventions. After completion of the run-in period,
only patients with persisting LDL-C levels >2.6 mmol/l were
randomized.
The exclusion criteria were: all forms of secondary
dyslipidemia; diabetes mellitus; dysfunction of the thyroid
gland, unless adequately treated; acute cardiovascular
disease, surgical procedures or inflammatory disease; all
conditions affecting plasma levels of cellular adhesion
molecules; active liver disease or hepatic dysfunction, as
defined by aminotransferase-values over 150% of upper limit
of normal; known allergic reaction to statins; clinically
manifest heart failure or severe cardiac arrhythmias; uncon-
trolled hypertension, as defined by a systolic blood pressure
>160 mmHg and/or a diastolic blood pressure >95 mmHg;
severe or unstable angina pectoris; excessive alcohol con-
sumption (over 4 units per day) ora history ofdrugabuse;use
of systemic steroids or androgens; impaired renal function
with plasma creatinine >150 μmol/l; a history of partial ileal
bypass surgery; inadequate contraceptive measures, pregnan-
cy or lactation in premenopausal women; baseline creatinine
phosfokinase values >150% upper limit of normal. The use of
all other lipid-lowering drugs and agents known to be
associated with rhabdomyolysis in combination with statins
were prohibited during the course of the study. Adverse
events were assessed at every visit in a nonspecific fashion
documenting any new or continuing symptoms since the
previous visit.
Measurements
To assess the lipid profile changes, total cholesterol (TC)
and triglycerides (TG) were measured at weeks −4 (i.e. start
of run-in), 0 (randomization visit), 8, and 16; high density
lipoprotein cholesterol (HDL-C) and LDL-C were mea-
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and HDL-C were determined by enzymatic methods on a
Vitros 950 (Ortho-Clinical Diagnostics, Rochester NY,
USA). HDL-C was isolated by precipitation of LDL and
VLDL with phosphotungstate and magnesiumchloride.
Serum LDL-C was calculated using the Friedewald
formula, excluding patients with serum TG levels
>5.0 mmol/l.
Inflammation markers and anti-oxLDL were assessed
during the randomization visit and after 16 weeks of study
treatment. CRP was measured using a routine high sen-
sitivity nephelometric method (Dade-Behring, Germany).
IgG anti-oxLDL antibodies were measured using an in
house sandwich-ELISA, of which details have been de-
scribed earlier [10]. In vitro oxLDL was generated by
modification of low density cholesterol with malondialde-
hyde as well as cupper. Anti-oxLDL values are presented as
levels of auto-antibodies against oxLDL relative to auto-
antibodies against native LDL. Levels of s-E-selectin and
s-ICAM-1 were analyzed by sandwich ELISA (British Bio-
technology Products) as described earlier [11]. Plasma level
of von Willebrand factor (vWF) was determined as the
amount of antigen using a sandwich-ELISA with OPD/
horse-radish peroxidase and subsequent UV detection
(Boehringer, Germany). Neopterin levels were quantified
by a commercially available radioimmunoassay (IMMU
test Neopterin, Germany). All assays had an inter- and
intra-assay coefficient of variation of <10%.
Ethics
The study design was approved by the local medical ethical
committees and written informed consent was obtained
from each participant.
Statistics
The study was powered at the difference in change in LDL-
C levels after 16 weeks of treatment from baseline between
both treatment groups, which was assessed using analysis
of covariance (ANCOVA), correcting for baseline levels of
LDL-C. To show at least a 5% difference in plasma LDL-C
levels between the atorvastatin treated- and simvastatin
treated group, and based on an inter-subject coefficient of
variation of 11%, a type 1 error of 0.05 and a power of
90%, a minimum of 106 patients was needed for each
group. To correct for premature discontinuation a total of
240 patients had to be included. In case of skewed
distribution, logarithmic transformation was performed. In
addition, potential differences at baseline were corrected for
by adding the variable as covariate to the ANCOVA
analysis. The same analysis methods were used for the
other variables, i.e. the difference in change in other lipids
and the biomarkers between both treatment groups.
Normal distribution of variables was tested with the
Kolmogorov-Smirnov test. Group mean differences between
Table 1 Baseline characteristics
Values are mean (SD), median
(P25–P75), or numbers (per-
centages) P value indicates
students
t-test for difference between
groups; *, P value for trend
Simvastatin Atorvastatin P value
Age (years) 58 (10) 58 (9) 0.65
Weight (kg) 82 (14) 86 (14) 0.11
Height (cm) 174 (9) 174 (9) 0.94
Body mass index (kg/m
2) 27.2 (3.6) 28.4 (4.1) 0.04
Systolic blood pressure (mmHg) 140 (130–150) 140 (130–150) 0.76
Diastolic blood pressure (mmHg) 80 (80–85) 80 (80–90) 0.29
Heart rate (BPM) 68 (10) 69 (10) 0.50
Total cholesterol (mmol/l) 5.62 (0.94) 5.72 (0.95) 0.48
Triglycerides (mmol/l) 1.61 (1.22–2.28) 1.64 (1.2–2.4) 0.64
HDL cholesterol (mmol/l) 1.16 (0.33) 1.16 (0.30) 1.00
LDL cholesterol (mmol/l) 3.59 (0.79) 3.70 (0.83) 0.40
Male gender 71 (77%) 75 (82%) 0.38
Smoking
Current 22 (24%) 30 (33%) 0.20*
Past 50 (54%) 49 (54%)
Never 20 (22%) 12 (13%)
History of hypertension 65 (71%) 63 (69%) 0.83
History of myocardial infarction 55 (60%) 53 (58%) 0.83
History of angina pectoris 63 (69%) 66 (73%) 0.55
History of claudication 11 (12%) 9 (10%) 0.65
History of cardiovascular intervention 55 (60%) 49 (54%) 0.36
History of other cardiovascular disease 21 (23%) 16 (18%) 0.36
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with unpaired t-tests. Paired t-tests were used to test the treat-
ment and non-treatment effects within the intervention and
non-intervention group, respectively. In case of categorical
variables the chi-square test or Fisher’s exact test was used.
Descriptive statistics are presented as mean values ± SD, as
median (inter quartile range) for skewed variables, or as
percentages. A two-sided P value<0.05 was considered
statistically significant. All statistical analyses were carried
out with the Statistical Package for Social Science (SPSS,
version 12.0.2, 24 March 2005).
Results
For this study, 331 potential patients were screened, of
which 235 patients were randomized: 119 were allocated to
receive simvastatin and 116 to receive atorvastatin. Of these
patients, 16 dropped out prematurely, of which 2 died (both
in simvastatin group), and 219 completed the study.
Furthermore, 44 patients were excluded after completion
because of protocol violation or missing/irretrievable/
unusable blood samples. Drop-out rates and excluded
patients were evenly distributed over both treatment groups
(Chi-Square, 0.58; P=0.75).
Patients who did not complete the study did not differ
significantly from patients who completed the study in
terms of demographic and lipid parameters, except for
HDL-C, which was significantly lower in these patients.
During the entire study period, 155 adverse events
occurred (simvastatin: 52 mild; 17 moderate; 6 severe;
atorvastatin: 52 mild; 24 moderate; 4 severe). There was
no difference between treatment groups (Chi-Square, 1.44;
P=0.49).
Baseline characteristics are outlined in Table 1. The two
groups of patients were well matched with regard to base-
line characteristics, with the exception of body mass index,
which was significantly higher in patients allocated to
atorvastatin.
Effect on lipids
The course of TC and TG levels during the study is
presented in Fig. 1, demonstrating that in the simvastatin
treated group TC increased slightly but significantly,
whereas TC decreased significantly in the atorvastatin
treated group. Additionally, TG levels decreased signifi-
cantly in the atorvastatin group only. Table 2 demonstrates
that also LDL-C was significantly reduced in the atorvas-
tatin group and increased in the simvastatin group.
After correction for baseline, the change in LDL-C from
baseline was significantly greater in atorvastatin treated
patients compared with simvastatin treated patients. Similar
effects were seen on TC and TG, whereas there was not a
significantly different effect on HDL-C.
Effect on biomarkers
Table 2 demonstrates the treatment effect on biomarkers
measured in this study. Aggressive lipid-lowering did not
have a significant effect on CRP, s-ICAM-1, s-E-selectin,
neopterin, and vWF when comparing 16 week levels with
baseline levels. In both treatment groups anti-oxLDL
decreased significantly. However after correction for base-
line, atorvastatin was not superior to simvastatin. Because
the groups differed on baseline body mass index, an
additional correction for body mass index was performed
when analyzing the treatment effect on all biomarkers. This
did not influence the results.
Patients with peripheral artery disease had higher levels
of CRP at baseline, but did not differ significantly on other
biomarkers. This group, however, was too small to assess
difference in treatment effect (i.e. N=19). Smokers (N=50)
also presented with higher median baseline levels of CRP
(4.1 (3.0–7.8) vs. 2.6 (1.6–7.1); P=0.001), but with no
differences in the other biomarkers. No significant differ-
ences in treatment effect between both statins were
observed (ANCOVA; P=0.098).
Fig. 1 Change in total cholesterol (a) and triglyceride (b) levels in
both treatment groups during the course of the study. Differences
between measurements were tested with the students t-test for paired
variables. * Indicates P value<0.05 comparing mean values between
baseline and 8 weeks, † for comparing mean values between 8 and
16 weeks, and ‡ comparing mean values between baseline and
16 weeks
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The results from this study confirm that intensifying lipid
lowering therapyfrom simvastatin 40 mgto atorvastatin 80 mg
is beneficial with regard to lowering TC, TG, and LDL-C after
16 weeks of therapy. However, the change in therapeutic
regimen did not result in lower levels of oxidative stress (anti-
oxLDL) and inflammatory and endothelial dysfunction bio-
markers (CRP, s-ICAM-1, s-E-selectin, neopterin, and vWF).
An intensive lipid lowering regimen with high dose statins
for secondary prevention has been proven to reduce mortality
and morbidity [1, 2, 12] and may significantly attenuate
atherosclerotic plaque progression [13–15]. Although the
additional LDL-C lowering effect of high dose statins is
beyond doubt an important mechanism in reducing the
atherosclerotic burden, some attribute a beneficial effect to
so-called pleiotropic activity of high dose statins [4]. It has
also been demonstrated that high dose statins are more
potent in lowering CRP compared with moderate dose
statins, but these results were obtained against a statin naïve
background [16]. Furthermore, CRP reduction was associat-
ed with a lower progression rate of the atherosclerotic
process as measured by intima media thickness [16]. These
data were confirmed in later studies [15, 17, 18]. In one of
these trials, reduction is CRP was independently associated
with less progression of atherosclerotic plaques, measured
with intravascular ultrasound [15].
Trials investigating the additional effect of aggressive
statin therapy on other biomarkers show inconsistent
results. Some studies support a beneficial effect on
fibrinogen, a well validated acute phase protein [17], but
this was not confirmed by other studies [19, 20]. Also a
beneficial effect on markers of haemostasis, including vWF
and endothelial activation has not been consistently shown
[17, 20]. A small study of 17 patients reported that the
enhanced LDL-C lowering effect of atorvastatin 10 mg
compared with pravastatin 20 mg also resulted in a
significantly greater reduction in malondialhyde modified
LDL [21]. However, in a sub-study from the ASAP trial, no
effect was seen of both regimens on anti-oxLDL or in vitro
susceptibility of LDL to oxidation [22].
Explanation of findings and study limitations
In current clinical practice most patients with established
CVD are already on standard dose statins for secondary
prevention. To our knowledge, no study has investigated
the additional effect of switching from standard to high
dose statin on inflammatory and oxidative stress biomarkers
in a randomized controlled trial. For example, the three
largest trials demonstrating beneficial effects of aggressive
statin therapy on CRP were preceded by a placebo run-in
phase [15, 16] or included predominantly statin naïve
patients [23]. Interestingly, in the PROVE-IT TIMI-22 trial,
Table 2 Treatment effect of both statins on lipids and biomarkers
Statin Baseline 16 Weeks Change (%) P value* P value
a
Total cholesterol S 5.62 (0.94) 5.77 (0.94) 2.8 0.036 <0.001
A 5.72 (0.95) 4.82 (1.00) −15.9 <0.001
Triglycerides S 1.88 (0.96) 1.89 (0.93) 0.8 0.82 0.002
A 1.89 (0.84) 1.61 (0.93) −15.0 <0.001
HDL cholesterol S 1.09 (0.96–1.39) 1.08 (0.94–1.34) −1.8 0.92 0.67
A 1.13 (0.93–1.35) 1.08 (0.88–1.38) −4.4 0.36
LDL cholesterol S 3.58 (0.79) 3.71 (0.88) 3.7 0.037 <0.001
A 3.72 (0.84) 2.95 (0.92) −20.8 <0.001
s-E-selectin S 50.0 (31.0–67.5) 46.0 (33.9–63.7) −1.0 0.64 0.55
A 46.4 (35.1–57.7) 45.9 (35.5–58.4) 1.2 0.59
s-ICAM-1 S 332.8 (288.8–387.5) 324.7 (274.1–382.4) −4.4 0.07 0.016
A 359.4 (301.5–412.5) 360.3 (308.3–439.6) 4.2 0.26
Neopterin S 1.9 (1.4–2.3) 1.8 (1.4–2.2) −1.0 0.53 0.16
A 1.8 (1.6–2.3) 1.9 (1.5–2.4) 5.4 0.15
vWF S 120 (100–150) 128 (99–158) 11.8 0.07 0.92
A 139 (108–190) 132 (105–209) 10.9 0.26
CRP S 1.5 (0.7–4.4) 1.1 (0.6–3.5) −61.3 0.15 0.071
A 1.8 (0.9–3.7) 2.1 (0.8–4.0) 15.3 0.86
Anti-oxLDL S 12.55 (8.23–18.53) 10.98 (7.21–14.46) −26.8 <0.001 0.25
A 13.83 (8.82–20.20) 12.46 (8.23–18.01) −13.4 <0.001
Values are mean (SD) or median (P25–P75); * indicates paired t-test or Wilcoxon singed rank test for baseline versus 16 weeks;
adifference in
treatment effect between simvastatin (S) and atorvastatin (A), corrected for baseline values; HDL, high density lipoprotein; LDL, low density
lipoprotein; s-E-selectin, soluble-endothelial-selectin; s-ICAM-1, soluble intercellular adhesion molecule-1; vWF, von Willebrand Factor; CRP,
C-reactive protein; anti-oxLDL, antibodies against oxidized low density lipoprotein
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naïve patients, whereas in those with prior statin therapy
(e.g. 25%), there was a neutral effect of both regimens and
only those patients with LDL-C levels >125 mg per deciliter
had an apparent benefit from aggressive statin therapy [1].
Another important issue is that, although experimental
studies suggest that inflammatory mediators other than CRP
may also by influenced by statin therapy [4], clinical
studies are not consistent. A large meta-analysis recently
reported that apart from the apparent beneficial effect on
CRP, current evidence does not support such an effect of
any statin compared with placebo on other biomarkers,
including oxLDL [24].
In subjects allocated to atorvastatin, there was a dose
escalation from 40 mg to 80 mg at week 8. Therefore, they
only received 80 mg for the final 8 weeks. It has been shown
that this time span is long enough to show a significant effect
on CRP [23], but the effect on other biomarkers after such a
short treatment period is questionable [25], although studies
have reported beneficial effects on oxLDL [26]. However,
the half life of IgG antibodies directed against oxLDL has
been shown to be around 15 days [27], and therefore
8 weeks should have been long enough to observe a
difference between two interventions, if present. Further-
more, whereas the mean LDL-C level achieved in the
aggressive statin group was 2.95 mmol/l, current guidelines
recommend that LDL-C reduction below 1.8 mmol/l is
reasonable [28]. Therefore, a future study is warranted to
investigate whether a greater reduction in LDL-C than
achieved in the current study will have a greater effect on
pleiotropic factors. Finally, it should be noted that, although
we did not observe a significant effect of aggressive statin
therapy on biomarkers studied in this study, this does not
preclude that this regimen could have beneficial effect on
the production of other inflammatory mediators such as
cytokines, chemokines, matrix metalloproteinases, nitric
oxide or the activation of nuclear factor kappa B.
Conclusions
The results from the current study do not support the
hypothesis that switching from conventional statin therapy
to aggressive statin therapy improves circulating levels of
specific oxidative stress and inflammatory biomarkers
measured in this study. As suggested in previous publica-
tions, our data do not support that the beneficial effect of
statin treatment on hard end points as reported in patients
with ACS or in other patients at high risk for major vascular
events can be attributed to a modulatory effect on the
inflammatory response [8, 29, 30]. Although a study of
longer duration or one studying other biomarkers is
warranted, our study does not provide evidence to intensify
statin treatment, merely for its anti-inflammatory effect in
secondary prevention patients that already have achieved
their LDL-C treatment goal.
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